NANOVIRICIDES, INC. Net Income (Loss) Available to Common Stockholders, Diluted
NANOVIRICIDES, INC. (NNVC) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$10.30 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-28.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2017-09-28
- NANOVIRICIDES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-06-30 was -$2.56M.
- NANOVIRICIDES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-03-31 was -$3.14M.
- NANOVIRICIDES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2016-12-31 was -$1.55M.
- NANOVIRICIDES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2016-09-30 was -$3.06M.
- NANOVIRICIDES, INC. net income (loss) available to common stockholders, diluted for fiscal 2017 was -$10.30M.
- NANOVIRICIDES, INC. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$10.72M.
- NANOVIRICIDES, INC. net income (loss) available to common stockholders, diluted for fiscal 2015 was -$5.28M.
- NANOVIRICIDES, INC. net income (loss) available to common stockholders, diluted for fiscal 2014 was -$13.60M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2017-06-30 | -$2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | -$5.70M derived: sum of 2 quarters · filed 2017-09-28 | -$7.24M derived: sum of 3 quarters · filed 2017-09-28 | -$10.30M 10-K · filed 2017-09-28 | |
| 2017-03-31 | -$3.14M 10-Q · filed 2017-05-15 | -$4.69M derived: sum of 2 quarters · filed 2017-05-15 | -$7.75M 10-Q · filed 2017-05-15 | -$9.40M derived: sum of 4 quarters · filed 2017-09-28 | |
| 2016-12-31 | -$1.55M 10-Q · filed 2017-02-14 | -$4.61M 10-Q · filed 2017-02-14 | -$6.26M derived: sum of 3 quarters · filed 2017-09-28 | -$11.25M derived: sum of 4 quarters · filed 2017-09-28 | |
| 2016-09-30 | -$3.06M 10-Q · filed 2016-11-14 | -$4.71M derived: sum of 2 quarters · filed 2017-09-28 | -$9.70M derived: sum of 3 quarters · filed 2017-09-28 | -$12.48M derived: sum of 4 quarters · filed 2017-09-28 | |
| 2016-06-30 | -$1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | -$6.64M derived: sum of 2 quarters · filed 2017-09-28 | -$9.42M derived: sum of 3 quarters · filed 2017-09-28 | -$10.72M 10-K · filed 2017-09-28 | |
| 2016-03-31 | -$4.99M 10-Q · filed 2017-05-15 | -$7.77M derived: sum of 2 quarters · filed 2017-05-15 | -$9.07M 10-Q · filed 2017-05-15 | -$10.33M derived: sum of 4 quarters · filed 2017-09-28 | |
| 2015-12-31 | -$2.78M 10-Q · filed 2017-02-14 | -$4.08M 10-Q · filed 2017-02-14 | -$5.34M derived: sum of 3 quarters · filed 2017-09-28 | -$6.28M derived: sum of 4 quarters · filed 2017-09-28 | |
| 2015-09-30 | -$1.31M 10-Q · filed 2016-11-14 | -$2.56M derived: sum of 2 quarters · filed 2017-09-28 | -$3.51M derived: sum of 3 quarters · filed 2017-09-28 | -$5.61M derived: sum of 4 quarters · filed 2017-09-28 | |
| 2015-06-30 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | -$2.20M derived: sum of 2 quarters · filed 2017-09-28 | -$4.31M derived: sum of 3 quarters · filed 2017-09-28 | -$5.28M 10-K · filed 2017-09-28 | |
| 2015-03-31 | -$947.12K 10-Q · filed 2016-05-10 | -$3.05M derived: sum of 2 quarters · filed 2016-05-10 | -$4.02M 10-Q · filed 2016-05-10 | -$4.02M 10-Q · filed 2015-05-15 | -$9.20M derived: sum of 4 quarters · filed 2016-09-16 |
| 2014-12-31 | -$2.10M 10-Q · filed 2016-02-09 | -$3.07M 10-Q · filed 2016-02-09 | -$8.25M derived: sum of 3 quarters · filed 2016-09-16 | -$9.43M derived: sum of 4 quarters · filed 2016-09-16 | |
| 2014-09-30 | $851.70K 10-Q · filed 2015-11-09 | -$6.15M derived: sum of 2 quarters · filed 2016-09-16 | -$7.33M derived: sum of 3 quarters · filed 2016-09-16 | -$8.69M derived: sum of 4 quarters · filed 2016-09-16 | |
| 2014-06-30 | -$7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-16 | -$8.18M derived: sum of 2 quarters · filed 2016-09-16 | -$9.54M derived: sum of 3 quarters · filed 2016-09-16 | -$13.60M 10-K · filed 2016-09-16 | |
| 2014-03-31 | -$1.18M 10-Q · filed 2015-05-15 | -$2.54M derived: sum of 2 quarters · filed 2015-05-15 | -$6.60M 10-Q · filed 2015-05-15 | ||
| 2013-12-31 | -$1.36M 10-Q · filed 2015-02-25 | -$7.93M 10-Q · filed 2015-02-25 | |||
| 2013-06-30 | -$9.21M 10-K · filed 2015-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |